Caribou Biosciences announced a strategic pipeline prioritization with workforce and cost reduction initiatives to focus resources on two lead oncology clinical programs.
Citing “challenges in the current market environment” Caribou will narrow focus to CB-010, a phase 1 allogeneic anti-CD19 CAR-T cell therapy for B cell non-Hodgkin lymphoma; and CB-011, a phase 1 allogeneic anti-BCMA CAR-T cell therapy for multiple myeloma. Caribou says clinical data disclosures are now planned for the second half of 2025.
The company will discontinue the phase 1 trial of CB-010 for lupus prior to dosing the first patient, as well as the phase 1 clinical trial of its allogeneic anti-CLL-1 CAR-T, CB-012, for relapsed or refractory acute myeloid leukemia.
The initiative also comes with a 32% workforce reduction. The company reported having 147 employees as of 2024.
For Caribou, this is the second culling in less than year. In July 2024, the company discontinued preclinical research activities associated with its allogeneic CAR-NK platform and reduced its workforce by 21 positions.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!